home / stock / blrx / blrx quote
Last: | $0.5753 |
---|---|
Change Percent: | -1.03% |
Open: | $0.6193 |
Close: | $0.5753 |
High: | $0.623 |
Low: | $0.5606 |
Volume: | 632,719 |
Last Trade Date Time: | 04/25/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.5753 | $0.6193 | $0.5753 | $0.623 | $0.5606 | 632,719 | 04-25-2024 |
$0.613 | $0.6174 | $0.613 | $0.6371 | $0.5908 | 758,823 | 04-24-2024 |
$0.6368 | $0.66 | $0.6368 | $0.67999 | $0.618 | 422,349 | 04-23-2024 |
$0.6771 | $0.6334 | $0.6771 | $0.6789 | $0.6334 | 176,118 | 04-22-2024 |
$0.6565 | $0.6616 | $0.6565 | $0.6799 | $0.6305 | 189,235 | 04-19-2024 |
$0.6401 | $0.64 | $0.6401 | $0.6649 | $0.6111 | 305,857 | 04-18-2024 |
$0.6214 | $0.6398 | $0.6214 | $0.6501 | $0.61 | 346,788 | 04-17-2024 |
$0.6394 | $0.64 | $0.6394 | $0.6713 | $0.62 | 253,025 | 04-16-2024 |
$0.6401 | $0.68 | $0.6401 | $0.7 | $0.63 | 654,617 | 04-15-2024 |
$0.7168 | $0.7 | $0.7168 | $0.72 | $0.6601 | 543,229 | 04-12-2024 |
$0.7 | $0.7 | $0.7 | $0.71 | $0.65 | 1,044,948 | 04-11-2024 |
$0.7357 | $0.7408 | $0.7357 | $0.75 | $0.66 | 1,405,883 | 04-10-2024 |
$0.7075 | $0.7655 | $0.7075 | $0.77455 | $0.69 | 1,108,890 | 04-09-2024 |
$0.7615 | $0.8375 | $0.7615 | $0.839 | $0.75 | 431,511 | 04-08-2024 |
$0.8108 | $0.82 | $0.8108 | $0.823 | $0.8031 | 342,719 | 04-05-2024 |
$0.8235 | $0.845 | $0.8235 | $0.845 | $0.8031 | 245,443 | 04-04-2024 |
$0.828 | $0.85 | $0.828 | $0.8579 | $0.801 | 572,577 | 04-03-2024 |
$0.8294 | $0.8819 | $0.8294 | $0.9305 | $0.82 | 730,433 | 04-02-2024 |
$0.8602 | $0.952 | $0.8602 | $1.1 | $0.85 | 2,241,272 | 04-01-2024 |
$1.12 | $1.12 | $1.12 | $1.13 | $1.1 | 163,193 | 03-29-2024 |
News, Short Squeeze, Breakout and More Instantly...
BioLineRx Ltd. Company Name:
BLRX Stock Symbol:
NASDAQ Market:
BioLineRx Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists including APHEXDA® (motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting PR Newswire TEL AVIV, Israel , April 17, 2024 /PRNewswire/ --...
BioLineRx Accesses Second Tranche of $20 Million Under Previously Announced $40 Million Non-Dilutive Debt Financing Agreement PR Newswire - Proceeds to be used to further accelerate uptake of APHEXDA® in stem cell mobilization, life-cycle expansion activities in sic...
BioLineRx Announces $6 Million Registered Direct Offering PR Newswire TEL AVIV, Israel , April 1, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) ("BioLineRx" or the "Company"), a commercial stage biopharmaceutical company pursuing life-changing t...